AstraZeneca said Monday that late-stage trials showed its COVID-19 vaccine with Oxford University was up to 90% effective in preventing disease. The results are based on interim analysis of trials in the U.K. and Brazil of a vaccine developed by Oxford University and manufactured by AstraZeneca. No hospitalizations or severe cases of COVID-19 were reported in those receiving the vaccine, AstraZeneca said.
The trial looked at two different dosing regimens. A half-dose of the vaccine followed by a full dose at least one month apart was 90% effective. A second regimen using two full doses one month apart was 62% effective. The combined results showed an average efficacy rate of 70%.
“These findings show that we have an effective vaccine that will save many lives,” Andrew Pollard, chief investigator for the trial, said in a statement. “Excitingly, we’ve found that one of our dosing regimens may be around 90% effective.”
AstraZeneca is the third major drug company to report late-stage results for its potential COVID-19 vaccine as public health officials anxiously wait for vaccines that will end the pandemic that has killed almost 1.4 million people. Last week, Pfizer and Moderna reported preliminary results from late-stage trials showing their vaccines were almost 95% effective.